Terms: = Ovarian cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Prognosis
38 results:
1. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
2. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
3. Autophagy-related gene PXN as a prognostic marker: Promotion of ovarian cancer progression by suppressing the p110β/Vps34/Beclin1 pathway.
Wu Q; Cui Z; Jiang S; Xia H; Liu L; You Y; Sun Y
Cell Biochem Funct; 2023 Jul; 41(5):599-608. PubMed ID: 37232085
[TBL] [Abstract] [Full Text] [Related]
4. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract] [Full Text] [Related]
5. Construction of an Immunity and Ferroptosis-Related Risk Score Model to Predict ovarian cancer Clinical Outcomes and Immune Microenvironment.
Wei C; Zhao G; Gao M; Liu Y; Lei P; Cao T
Front Biosci (Landmark Ed); 2023 Jan; 28(1):4. PubMed ID: 36722270
[TBL] [Abstract] [Full Text] [Related]
6. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract] [Full Text] [Related]
7. Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.
Zhang X; Kong W; Gao M; Huang W; Peng C; Huang Z; Xie Z; Guo H
J Cell Mol Med; 2022 Jul; 26(13):3659-3674. PubMed ID: 35735060
[TBL] [Abstract] [Full Text] [Related]
8. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract] [Full Text] [Related]
9. A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma.
Yu Z; He H; Chen Y; Ji Q; Sun M
Sci Rep; 2021 Jun; 11(1):11486. PubMed ID: 34075060
[TBL] [Abstract] [Full Text] [Related]
10. Construction autophagy-related prognostic risk signature to facilitate survival prediction, individual treatment and biomarker excavation of epithelial ovarian cancer patients.
Fei H; Chen S; Xu C
J Ovarian Res; 2021 Mar; 14(1):41. PubMed ID: 33676525
[TBL] [Abstract] [Full Text] [Related]
11. Hypoxia Alters the Response to Anti-EGFR Therapy by Regulating EGFR Expression and Downstream Signaling in a DNA Methylation-Specific and HIF-Dependent Manner.
Mamo M; Ye IC; DiGiacomo JW; Park JY; Downs B; Gilkes DM
Cancer Res; 2020 Nov; 80(22):4998-5010. PubMed ID: 33023947
[TBL] [Abstract] [Full Text] [Related]
12. A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Bantie L; Tadesse S; Likisa J; Yu M; Noll B; Heinemann G; Lokman NA; Ricciardelli C; Oehler MK; Beck A; Pradhan R; Milne R; Albrecht H; Wang S
Gynecol Oncol; 2020 Dec; 159(3):827-838. PubMed ID: 32958271
[TBL] [Abstract] [Full Text] [Related]
13. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.
Bayard Q; Meunier L; Peneau C; Renault V; Shinde J; Nault JC; Mami I; Couchy G; Amaddeo G; Tubacher E; Bacq D; Meyer V; La Bella T; Debaillon-Vesque A; Bioulac-Sage P; Seror O; Blanc JF; Calderaro J; Deleuze JF; Imbeaud S; Zucman-Rossi J; Letouzé E
Nat Commun; 2018 Dec; 9(1):5235. PubMed ID: 30531861
[TBL] [Abstract] [Full Text] [Related]
14. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.
Iness AN; Felthousen J; Ananthapadmanabhan V; Sesay F; Saini S; Guiley KZ; Rubin SM; Dozmorov M; Litovchick L
Oncogene; 2019 Feb; 38(7):1080-1092. PubMed ID: 30206359
[TBL] [Abstract] [Full Text] [Related]
15. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
[TBL] [Abstract] [Full Text] [Related]
16. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous ovarian cancer.
Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
[No Abstract] [Full Text] [Related]
17. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Characterization of High-Grade Serous ovarian cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract] [Full Text] [Related]
19. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer.
Deng Y; Jiang L; Wang Y; Xi Q; Zhong J; Liu J; Yang S; Liu R; Wang J; Huang M; Tang C; Su M
Pathol Res Pract; 2016 Apr; 212(4):239-46. PubMed ID: 26920249
[TBL] [Abstract] [Full Text] [Related]
20. Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women.
Kato S; Abarzua-Catalan L; Trigo C; Delpiano A; Sanhueza C; García K; Ibañez C; Hormazábal K; Diaz D; Brañes J; Castellón E; Bravo E; Owen G; Cuello MA
Oncotarget; 2015 Aug; 6(25):21100-19. PubMed ID: 26053184
[TBL] [Abstract] [Full Text] [Related]
[Next]
